nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—LHCGR—corpus luteum—breast cancer	0.143	0.712	CbGeAlD
Goserelin—LHCGR—adipose tissue—breast cancer	0.00997	0.0496	CbGeAlD
Goserelin—LHCGR—female reproductive system—breast cancer	0.00916	0.0456	CbGeAlD
Goserelin—LHCGR—female gonad—breast cancer	0.00834	0.0415	CbGeAlD
Goserelin—LHCGR—endocrine gland—breast cancer	0.00775	0.0386	CbGeAlD
Goserelin—GNRHR—pituitary gland—breast cancer	0.00645	0.0321	CbGeAlD
Goserelin—GNRHR—female reproductive system—breast cancer	0.0059	0.0294	CbGeAlD
Goserelin—GNRHR—female gonad—breast cancer	0.00537	0.0267	CbGeAlD
Goserelin—GNRHR—endocrine gland—breast cancer	0.005	0.0249	CbGeAlD
Goserelin—Pentagastrin—BCHE—breast cancer	0.00156	1	CrCbGaD
Goserelin—GNRHR—Signaling by GPCR—AGTR1—breast cancer	0.000133	0.000622	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CALCA—breast cancer	0.000133	0.000621	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ITPR1—breast cancer	0.000132	0.000615	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RPS6—breast cancer	0.000132	0.000614	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF4—breast cancer	0.000131	0.000609	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCR4—breast cancer	0.00013	0.000607	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCL12—breast cancer	0.00013	0.000607	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TLE3—breast cancer	0.00013	0.000604	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—LPAR1—breast cancer	0.00013	0.000604	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HEY1—breast cancer	0.000128	0.000598	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PAK1—breast cancer	0.000128	0.000596	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—DLL1—breast cancer	0.000126	0.000586	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TCF7L2—breast cancer	0.000126	0.000585	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AKT2—breast cancer	0.000125	0.000583	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CG—breast cancer	0.000124	0.000578	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	0.000124	0.000578	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HIST1H2BC—breast cancer	0.000123	0.000575	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HIST1H2BK—breast cancer	0.000123	0.000575	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GRB7—breast cancer	0.000122	0.00057	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDE4D—breast cancer	0.000122	0.00057	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CSF2—breast cancer	0.000122	0.000568	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NOTCH2—breast cancer	0.000121	0.000564	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HSP90AA1—breast cancer	0.000121	0.000564	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TAB2—breast cancer	0.00012	0.00056	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CD—breast cancer	0.00012	0.00056	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ITPR1—breast cancer	0.00012	0.000558	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CNR2—breast cancer	0.000119	0.000556	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—CXCL8—breast cancer	0.000119	0.000555	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—MMP3—breast cancer	0.000119	0.000554	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	0.000119	0.000553	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRL—breast cancer	0.000118	0.000549	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AGTR1—breast cancer	0.000118	0.000549	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—DKK1—breast cancer	0.000116	0.000542	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ADAM10—breast cancer	0.000116	0.000541	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STK11—breast cancer	0.000116	0.000541	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFC—breast cancer	0.000115	0.000538	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PLG—breast cancer	0.000115	0.000535	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JAG2—breast cancer	0.000114	0.00053	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AKT2—breast cancer	0.000113	0.000529	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF10—breast cancer	0.000113	0.000526	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—WNT1—breast cancer	0.000112	0.000523	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PLA2G4A—breast cancer	0.000112	0.000521	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CSF2—breast cancer	0.000111	0.000515	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CD—breast cancer	0.000109	0.000508	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PDGFA—breast cancer	0.000109	0.000508	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TGFBR2—breast cancer	0.000107	0.000501	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NOTCH4—breast cancer	0.000106	0.000495	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ITPR1—breast cancer	0.000106	0.000493	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—GZMB—breast cancer	0.000106	0.000492	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MMP3—breast cancer	0.000105	0.000489	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT5A—breast cancer	0.000105	0.000489	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ERBB4—breast cancer	0.000105	0.000489	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CB—breast cancer	0.000105	0.000488	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AGTR2—breast cancer	0.000103	0.000478	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL2—breast cancer	0.000103	0.000478	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SMAD4—breast cancer	0.000102	0.000474	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTHLH—breast cancer	0.000101	0.000473	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BMP2—breast cancer	0.000101	0.000473	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IGF1R—breast cancer	0.000101	0.000471	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CXCL8—breast cancer	0.000101	0.000469	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HES1—breast cancer	9.93e-05	0.000463	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PLA2G4A—breast cancer	9.87e-05	0.00046	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NCOR1—breast cancer	9.87e-05	0.00046	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EDNRB—breast cancer	9.82e-05	0.000458	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGF1—breast cancer	9.76e-05	0.000455	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CSF2—breast cancer	9.76e-05	0.000455	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—RAF1—breast cancer	9.74e-05	0.000454	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PGR—breast cancer	9.72e-05	0.000453	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NRG1—breast cancer	9.69e-05	0.000452	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—THBS1—breast cancer	9.67e-05	0.000451	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—H2AFX—breast cancer	9.62e-05	0.000448	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—IL2—breast cancer	9.61e-05	0.000448	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—E2F1—breast cancer	9.55e-05	0.000445	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CB—breast cancer	9.5e-05	0.000443	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FLT1—breast cancer	9.23e-05	0.00043	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SQSTM1—breast cancer	9.19e-05	0.000428	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF3—breast cancer	9.19e-05	0.000428	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SPP1—breast cancer	9.17e-05	0.000428	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CG—breast cancer	9.14e-05	0.000426	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CXCL8—breast cancer	9.13e-05	0.000426	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ERBB3—breast cancer	9.07e-05	0.000423	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JAG1—breast cancer	9.07e-05	0.000423	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGFR2—breast cancer	9.06e-05	0.000422	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NOTCH3—breast cancer	9.03e-05	0.000421	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PARP1—breast cancer	9.03e-05	0.000421	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CALCA—breast cancer	8.92e-05	0.000416	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RPS6—breast cancer	8.82e-05	0.000411	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF4—breast cancer	8.75e-05	0.000408	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL2—breast cancer	8.73e-05	0.000407	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL12—breast cancer	8.72e-05	0.000406	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCR4—breast cancer	8.72e-05	0.000406	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TERT—breast cancer	8.7e-05	0.000405	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PAK1—breast cancer	8.56e-05	0.000399	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FGFR1—breast cancer	8.44e-05	0.000394	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TCF7L2—breast cancer	8.41e-05	0.000392	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AKT2—breast cancer	8.37e-05	0.00039	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HIF1A—breast cancer	8.32e-05	0.000388	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CG—breast cancer	8.3e-05	0.000387	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—LEP—breast cancer	8.12e-05	0.000378	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HSP90AA1—breast cancer	8.1e-05	0.000378	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NOTCH2—breast cancer	8.1e-05	0.000378	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CAV1—breast cancer	8.04e-05	0.000375	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CD—breast cancer	8.04e-05	0.000375	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KDR—breast cancer	7.95e-05	0.000371	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRL—breast cancer	7.88e-05	0.000367	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AGTR1—breast cancer	7.88e-05	0.000367	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STK11—breast cancer	7.77e-05	0.000362	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ADAM10—breast cancer	7.77e-05	0.000362	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ESR1—breast cancer	7.75e-05	0.000361	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PLG—breast cancer	7.68e-05	0.000358	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FN1—breast cancer	7.66e-05	0.000357	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AKT2—breast cancer	7.6e-05	0.000354	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NFKBIA—breast cancer	7.57e-05	0.000353	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF10—breast cancer	7.56e-05	0.000352	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NOTCH1—breast cancer	7.49e-05	0.000349	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KIT—breast cancer	7.33e-05	0.000342	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CG—breast cancer	7.33e-05	0.000342	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—APC—breast cancer	7.33e-05	0.000342	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CD—breast cancer	7.3e-05	0.00034	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PDGFA—breast cancer	7.29e-05	0.00034	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EGF—breast cancer	7.24e-05	0.000338	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFBR2—breast cancer	7.19e-05	0.000335	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ITPR1—breast cancer	7.07e-05	0.00033	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ERBB4—breast cancer	7.03e-05	0.000328	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MMP3—breast cancer	7.03e-05	0.000328	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT5A—breast cancer	7.03e-05	0.000328	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—MAPK3—breast cancer	7.02e-05	0.000327	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CB—breast cancer	7.01e-05	0.000327	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BRAF—breast cancer	6.89e-05	0.000321	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SMAD4—breast cancer	6.8e-05	0.000317	CbGpPWpGaD
Goserelin—Headache—Gemcitabine—breast cancer	6.77e-05	0.000116	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IGF1R—breast cancer	6.76e-05	0.000315	CbGpPWpGaD
Goserelin—Musculoskeletal discomfort—Capecitabine—breast cancer	6.76e-05	0.000116	CcSEcCtD
Goserelin—Cardiac disorder—Epirubicin—breast cancer	6.75e-05	0.000116	CcSEcCtD
Goserelin—Vomiting—Fluorouracil—breast cancer	6.75e-05	0.000116	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—breast cancer	6.75e-05	0.000116	CcSEcCtD
Goserelin—Dyspepsia—Docetaxel—breast cancer	6.75e-05	0.000116	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—breast cancer	6.73e-05	0.000115	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—breast cancer	6.73e-05	0.000115	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—CXCL8—breast cancer	6.73e-05	0.000314	CbGpPWpGaD
Goserelin—Insomnia—Capecitabine—breast cancer	6.71e-05	0.000115	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IGF1—breast cancer	6.71e-05	0.000313	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKT2—breast cancer	6.7e-05	0.000313	CbGpPWpGaD
Goserelin—Rash—Fluorouracil—breast cancer	6.7e-05	0.000115	CcSEcCtD
Goserelin—Dermatitis—Fluorouracil—breast cancer	6.69e-05	0.000115	CcSEcCtD
Goserelin—Pharyngitis—Doxorubicin—breast cancer	6.68e-05	0.000115	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—EGFR—breast cancer	6.68e-05	0.000311	CbGpPWpGaD
Goserelin—Paraesthesia—Capecitabine—breast cancer	6.66e-05	0.000114	CcSEcCtD
Goserelin—Decreased appetite—Docetaxel—breast cancer	6.66e-05	0.000114	CcSEcCtD
Goserelin—Hypersensitivity—Paclitaxel—breast cancer	6.66e-05	0.000114	CcSEcCtD
Goserelin—Headache—Fluorouracil—breast cancer	6.65e-05	0.000114	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—breast cancer	6.65e-05	0.000114	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HES1—breast cancer	6.64e-05	0.00031	CbGpPWpGaD
Goserelin—Oedema peripheral—Doxorubicin—breast cancer	6.63e-05	0.000114	CcSEcCtD
Goserelin—Dyspnoea—Capecitabine—breast cancer	6.62e-05	0.000113	CcSEcCtD
Goserelin—Fatigue—Docetaxel—breast cancer	6.61e-05	0.000113	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—NCOR1—breast cancer	6.61e-05	0.000308	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PLA2G4A—breast cancer	6.61e-05	0.000308	CbGpPWpGaD
Goserelin—Angiopathy—Epirubicin—breast cancer	6.6e-05	0.000113	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—breast cancer	6.6e-05	0.000113	CcSEcCtD
Goserelin—Nausea—Irinotecan—breast cancer	6.59e-05	0.000113	CcSEcCtD
Goserelin—Nausea—Mitoxantrone—breast cancer	6.59e-05	0.000113	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—breast cancer	6.57e-05	0.000113	CcSEcCtD
Goserelin—Pain—Docetaxel—breast cancer	6.56e-05	0.000112	CcSEcCtD
Goserelin—Constipation—Docetaxel—breast cancer	6.56e-05	0.000112	CcSEcCtD
Goserelin—Back pain—Methotrexate—breast cancer	6.55e-05	0.000112	CcSEcCtD
Goserelin—Dyspepsia—Capecitabine—breast cancer	6.53e-05	0.000112	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CSF2—breast cancer	6.53e-05	0.000305	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGF1—breast cancer	6.53e-05	0.000305	CbGpPWpGaD
Goserelin—Chills—Epirubicin—breast cancer	6.53e-05	0.000112	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—RAF1—breast cancer	6.52e-05	0.000304	CbGpPWpGaD
Goserelin—Arrhythmia—Epirubicin—breast cancer	6.5e-05	0.000112	CcSEcCtD
Goserelin—Asthenia—Paclitaxel—breast cancer	6.49e-05	0.000111	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—NRG1—breast cancer	6.48e-05	0.000302	CbGpPWpGaD
Goserelin—Decreased appetite—Capecitabine—breast cancer	6.45e-05	0.000111	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CD—breast cancer	6.44e-05	0.0003	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—H2AFX—breast cancer	6.44e-05	0.0003	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2—breast cancer	6.43e-05	0.0003	CbGpPWpGaD
Goserelin—Alopecia—Epirubicin—breast cancer	6.43e-05	0.00011	CcSEcCtD
Goserelin—Nausea—Gemcitabine—breast cancer	6.42e-05	0.00011	CcSEcCtD
Goserelin—Fatigue—Capecitabine—breast cancer	6.4e-05	0.00011	CcSEcCtD
Goserelin—Pruritus—Paclitaxel—breast cancer	6.4e-05	0.00011	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—E2F1—breast cancer	6.39e-05	0.000298	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—breast cancer	6.38e-05	0.000297	CbGpPWpGaD
Goserelin—Vision blurred—Methotrexate—breast cancer	6.38e-05	0.000109	CcSEcCtD
Goserelin—Mental disorder—Epirubicin—breast cancer	6.38e-05	0.000109	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SERPINE1—breast cancer	6.37e-05	0.000297	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CB—breast cancer	6.36e-05	0.000297	CbGpPWpGaD
Goserelin—Pain—Capecitabine—breast cancer	6.35e-05	0.000109	CcSEcCtD
Goserelin—Constipation—Capecitabine—breast cancer	6.35e-05	0.000109	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—breast cancer	6.34e-05	0.000109	CcSEcCtD
Goserelin—Erythema—Epirubicin—breast cancer	6.34e-05	0.000109	CcSEcCtD
Goserelin—Feeling abnormal—Docetaxel—breast cancer	6.32e-05	0.000108	CcSEcCtD
Goserelin—Nausea—Fluorouracil—breast cancer	6.31e-05	0.000108	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—KRAS—breast cancer	6.31e-05	0.000294	CbGpPWpGaD
Goserelin—Eye disorder—Doxorubicin—breast cancer	6.29e-05	0.000108	CcSEcCtD
Goserelin—Ill-defined disorder—Methotrexate—breast cancer	6.28e-05	0.000108	CcSEcCtD
Goserelin—Gastrointestinal pain—Docetaxel—breast cancer	6.27e-05	0.000108	CcSEcCtD
Goserelin—Anaemia—Methotrexate—breast cancer	6.26e-05	0.000107	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—breast cancer	6.25e-05	0.000107	CcSEcCtD
Goserelin—Flatulence—Epirubicin—breast cancer	6.24e-05	0.000107	CcSEcCtD
Goserelin—Tension—Epirubicin—breast cancer	6.22e-05	0.000107	CcSEcCtD
Goserelin—Diarrhoea—Paclitaxel—breast cancer	6.19e-05	0.000106	CcSEcCtD
Goserelin—Nervousness—Epirubicin—breast cancer	6.15e-05	0.000106	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SPP1—breast cancer	6.14e-05	0.000286	CbGpPWpGaD
Goserelin—Back pain—Epirubicin—breast cancer	6.13e-05	0.000105	CcSEcCtD
Goserelin—Feeling abnormal—Capecitabine—breast cancer	6.12e-05	0.000105	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—CXCL8—breast cancer	6.11e-05	0.000285	CbGpPWpGaD
Goserelin—Angiopathy—Doxorubicin—breast cancer	6.11e-05	0.000105	CcSEcCtD
Goserelin—Malaise—Methotrexate—breast cancer	6.11e-05	0.000105	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—breast cancer	6.09e-05	0.000104	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—NOS3—breast cancer	6.08e-05	0.000284	CbGpPWpGaD
Goserelin—Immune system disorder—Doxorubicin—breast cancer	6.08e-05	0.000104	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ERBB3—breast cancer	6.07e-05	0.000283	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Capecitabine—breast cancer	6.07e-05	0.000104	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FGFR2—breast cancer	6.07e-05	0.000283	CbGpPWpGaD
Goserelin—Abdominal pain—Docetaxel—breast cancer	6.06e-05	0.000104	CcSEcCtD
Goserelin—Body temperature increased—Docetaxel—breast cancer	6.06e-05	0.000104	CcSEcCtD
Goserelin—Leukopenia—Methotrexate—breast cancer	6.06e-05	0.000104	CcSEcCtD
Goserelin—Chills—Doxorubicin—breast cancer	6.04e-05	0.000104	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—breast cancer	6.02e-05	0.000103	CcSEcCtD
Goserelin—Dizziness—Paclitaxel—breast cancer	5.98e-05	0.000103	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—breast cancer	5.97e-05	0.000102	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—breast cancer	5.95e-05	0.000102	CcSEcCtD
Goserelin—Cough—Methotrexate—breast cancer	5.91e-05	0.000101	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—breast cancer	5.9e-05	0.000101	CcSEcCtD
Goserelin—Urticaria—Capecitabine—breast cancer	5.9e-05	0.000101	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—breast cancer	5.88e-05	0.000101	CcSEcCtD
Goserelin—Body temperature increased—Capecitabine—breast cancer	5.87e-05	0.000101	CcSEcCtD
Goserelin—Abdominal pain—Capecitabine—breast cancer	5.87e-05	0.000101	CcSEcCtD
Goserelin—Convulsion—Methotrexate—breast cancer	5.87e-05	0.000101	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—breast cancer	5.86e-05	0.000101	CcSEcCtD
Goserelin—Erythema—Doxorubicin—breast cancer	5.86e-05	0.000101	CcSEcCtD
Goserelin—Anaemia—Epirubicin—breast cancer	5.86e-05	0.0001	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—IL2—breast cancer	5.84e-05	0.000272	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TERT—breast cancer	5.82e-05	0.000271	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—breast cancer	5.79e-05	0.00027	CbGpPWpGaD
Goserelin—Flatulence—Doxorubicin—breast cancer	5.78e-05	9.91e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MDM2—breast cancer	5.77e-05	0.000269	CbGpPWpGaD
Goserelin—Arthralgia—Methotrexate—breast cancer	5.76e-05	9.88e-05	CcSEcCtD
Goserelin—Myalgia—Methotrexate—breast cancer	5.76e-05	9.88e-05	CcSEcCtD
Goserelin—Chest pain—Methotrexate—breast cancer	5.76e-05	9.88e-05	CcSEcCtD
Goserelin—Tension—Doxorubicin—breast cancer	5.75e-05	9.87e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—RAF1—breast cancer	5.75e-05	0.000268	CbGpPWpGaD
Goserelin—Vomiting—Paclitaxel—breast cancer	5.75e-05	9.86e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—RELA—breast cancer	5.73e-05	0.000267	CbGpPWpGaD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	5.72e-05	9.82e-05	CcSEcCtD
Goserelin—Malaise—Epirubicin—breast cancer	5.71e-05	9.8e-05	CcSEcCtD
Goserelin—Rash—Paclitaxel—breast cancer	5.7e-05	9.78e-05	CcSEcCtD
Goserelin—Dermatitis—Paclitaxel—breast cancer	5.7e-05	9.77e-05	CcSEcCtD
Goserelin—Discomfort—Methotrexate—breast cancer	5.69e-05	9.77e-05	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—breast cancer	5.69e-05	9.76e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—ERBB2—breast cancer	5.69e-05	0.000265	CbGpPWpGaD
Goserelin—Leukopenia—Epirubicin—breast cancer	5.67e-05	9.73e-05	CcSEcCtD
Goserelin—Back pain—Doxorubicin—breast cancer	5.67e-05	9.72e-05	CcSEcCtD
Goserelin—Headache—Paclitaxel—breast cancer	5.67e-05	9.72e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FGFR1—breast cancer	5.65e-05	0.000264	CbGpPWpGaD
Goserelin—Hypersensitivity—Docetaxel—breast cancer	5.65e-05	9.69e-05	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—breast cancer	5.64e-05	9.67e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MTOR—breast cancer	5.61e-05	0.000262	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CB—breast cancer	5.61e-05	0.000262	CbGpPWpGaD
Goserelin—Palpitations—Epirubicin—breast cancer	5.6e-05	9.6e-05	CcSEcCtD
Goserelin—Confusional state—Methotrexate—breast cancer	5.57e-05	9.55e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—HIF1A—breast cancer	5.57e-05	0.00026	CbGpPWpGaD
Goserelin—Cough—Epirubicin—breast cancer	5.53e-05	9.48e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Methotrexate—breast cancer	5.53e-05	9.48e-05	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—breast cancer	5.52e-05	9.47e-05	CcSEcCtD
Goserelin—Asthenia—Docetaxel—breast cancer	5.5e-05	9.43e-05	CcSEcCtD
Goserelin—Convulsion—Epirubicin—breast cancer	5.49e-05	9.41e-05	CcSEcCtD
Goserelin—Infection—Methotrexate—breast cancer	5.49e-05	9.41e-05	CcSEcCtD
Goserelin—Hypertension—Epirubicin—breast cancer	5.47e-05	9.38e-05	CcSEcCtD
Goserelin—Hypersensitivity—Capecitabine—breast cancer	5.47e-05	9.38e-05	CcSEcCtD
Goserelin—Ill-defined disorder—Doxorubicin—breast cancer	5.44e-05	9.33e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—LEP—breast cancer	5.44e-05	0.000253	CbGpPWpGaD
Goserelin—Pruritus—Docetaxel—breast cancer	5.42e-05	9.3e-05	CcSEcCtD
Goserelin—Nervous system disorder—Methotrexate—breast cancer	5.42e-05	9.29e-05	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—breast cancer	5.42e-05	9.29e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Methotrexate—breast cancer	5.41e-05	9.28e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CXCL8—breast cancer	5.4e-05	0.000252	CbGpPWpGaD
Goserelin—Myalgia—Epirubicin—breast cancer	5.39e-05	9.25e-05	CcSEcCtD
Goserelin—Chest pain—Epirubicin—breast cancer	5.39e-05	9.25e-05	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—breast cancer	5.39e-05	9.25e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CAV1—breast cancer	5.39e-05	0.000251	CbGpPWpGaD
Goserelin—Anxiety—Epirubicin—breast cancer	5.38e-05	9.22e-05	CcSEcCtD
Goserelin—Nausea—Paclitaxel—breast cancer	5.37e-05	9.21e-05	CcSEcCtD
Goserelin—Skin disorder—Methotrexate—breast cancer	5.37e-05	9.2e-05	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—HRAS—breast cancer	5.36e-05	0.00025	CbGpPWpGaD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.36e-05	9.19e-05	CcSEcCtD
Goserelin—Hyperhidrosis—Methotrexate—breast cancer	5.34e-05	9.16e-05	CcSEcCtD
Goserelin—Discomfort—Epirubicin—breast cancer	5.33e-05	9.14e-05	CcSEcCtD
Goserelin—Asthenia—Capecitabine—breast cancer	5.33e-05	9.13e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—KDR—breast cancer	5.32e-05	0.000248	CbGpPWpGaD
Goserelin—Malaise—Doxorubicin—breast cancer	5.29e-05	9.07e-05	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—breast cancer	5.28e-05	9.05e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CDKN1B—breast cancer	5.27e-05	0.000246	CbGpPWpGaD
Goserelin—Anorexia—Methotrexate—breast cancer	5.27e-05	9.03e-05	CcSEcCtD
Goserelin—Pruritus—Capecitabine—breast cancer	5.25e-05	9.01e-05	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—breast cancer	5.25e-05	9e-05	CcSEcCtD
Goserelin—Diarrhoea—Docetaxel—breast cancer	5.25e-05	9e-05	CcSEcCtD
Goserelin—Confusional state—Epirubicin—breast cancer	5.21e-05	8.94e-05	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—breast cancer	5.21e-05	0.000243	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ESR1—breast cancer	5.19e-05	0.000242	CbGpPWpGaD
Goserelin—Palpitations—Doxorubicin—breast cancer	5.18e-05	8.88e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—breast cancer	5.17e-05	8.87e-05	CcSEcCtD
Goserelin—Oedema—Epirubicin—breast cancer	5.17e-05	8.87e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CASP3—breast cancer	5.16e-05	0.000241	CbGpPWpGaD
Goserelin—Hypotension—Methotrexate—breast cancer	5.16e-05	8.85e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL2—breast cancer	5.16e-05	0.00024	CbGpPWpGaD
Goserelin—Infection—Epirubicin—breast cancer	5.14e-05	8.81e-05	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—IL6—breast cancer	5.13e-05	0.000239	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FN1—breast cancer	5.13e-05	0.000239	CbGpPWpGaD
Goserelin—Cough—Doxorubicin—breast cancer	5.12e-05	8.77e-05	CcSEcCtD
Goserelin—Shock—Epirubicin—breast cancer	5.09e-05	8.72e-05	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—breast cancer	5.08e-05	8.71e-05	CcSEcCtD
Goserelin—Diarrhoea—Capecitabine—breast cancer	5.08e-05	8.71e-05	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—breast cancer	5.07e-05	8.7e-05	CcSEcCtD
Goserelin—Dizziness—Docetaxel—breast cancer	5.07e-05	8.69e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—NFKBIA—breast cancer	5.06e-05	0.000236	CbGpPWpGaD
Goserelin—Thrombocytopenia—Epirubicin—breast cancer	5.06e-05	8.68e-05	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—breast cancer	5.06e-05	8.68e-05	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—breast cancer	5.05e-05	8.65e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Methotrexate—breast cancer	5.03e-05	8.63e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CCND1—breast cancer	5.03e-05	0.000234	CbGpPWpGaD
Goserelin—Skin disorder—Epirubicin—breast cancer	5.02e-05	8.61e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—NOTCH1—breast cancer	5.02e-05	0.000234	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JUN—breast cancer	5.02e-05	0.000234	CbGpPWpGaD
Goserelin—Hyperhidrosis—Epirubicin—breast cancer	5e-05	8.57e-05	CcSEcCtD
Goserelin—Insomnia—Methotrexate—breast cancer	5e-05	8.57e-05	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—breast cancer	4.99e-05	8.56e-05	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—breast cancer	4.99e-05	8.56e-05	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—breast cancer	4.99e-05	8.56e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CTNNB1—breast cancer	4.98e-05	0.000232	CbGpPWpGaD
Goserelin—Anxiety—Doxorubicin—breast cancer	4.97e-05	8.53e-05	CcSEcCtD
Goserelin—Paraesthesia—Methotrexate—breast cancer	4.96e-05	8.51e-05	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.96e-05	8.5e-05	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—breast cancer	4.93e-05	8.46e-05	CcSEcCtD
Goserelin—Anorexia—Epirubicin—breast cancer	4.93e-05	8.45e-05	CcSEcCtD
Goserelin—Dyspnoea—Methotrexate—breast cancer	4.93e-05	8.45e-05	CcSEcCtD
Goserelin—Somnolence—Methotrexate—breast cancer	4.91e-05	8.42e-05	CcSEcCtD
Goserelin—Dizziness—Capecitabine—breast cancer	4.91e-05	8.42e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3CG—breast cancer	4.91e-05	0.000229	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KIT—breast cancer	4.91e-05	0.000229	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—APC—breast cancer	4.91e-05	0.000229	CbGpPWpGaD
Goserelin—Dry mouth—Doxorubicin—breast cancer	4.88e-05	8.37e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MMP9—breast cancer	4.88e-05	0.000228	CbGpPWpGaD
Goserelin—Vomiting—Docetaxel—breast cancer	4.87e-05	8.36e-05	CcSEcCtD
Goserelin—Dyspepsia—Methotrexate—breast cancer	4.86e-05	8.34e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CDKN1A—breast cancer	4.86e-05	0.000227	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTEN—breast cancer	4.85e-05	0.000226	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGF—breast cancer	4.85e-05	0.000226	CbGpPWpGaD
Goserelin—Rash—Docetaxel—breast cancer	4.83e-05	8.29e-05	CcSEcCtD
Goserelin—Hypotension—Epirubicin—breast cancer	4.83e-05	8.29e-05	CcSEcCtD
Goserelin—Dermatitis—Docetaxel—breast cancer	4.83e-05	8.28e-05	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—breast cancer	4.82e-05	8.27e-05	CcSEcCtD
Goserelin—Decreased appetite—Methotrexate—breast cancer	4.8e-05	8.24e-05	CcSEcCtD
Goserelin—Headache—Docetaxel—breast cancer	4.8e-05	8.24e-05	CcSEcCtD
Goserelin—Oedema—Doxorubicin—breast cancer	4.78e-05	8.2e-05	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—breast cancer	4.78e-05	8.2e-05	CcSEcCtD
Goserelin—Fatigue—Methotrexate—breast cancer	4.76e-05	8.17e-05	CcSEcCtD
Goserelin—Infection—Doxorubicin—breast cancer	4.75e-05	8.15e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MAPK8—breast cancer	4.75e-05	0.000221	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AKT1—breast cancer	4.73e-05	0.000221	CbGpPWpGaD
Goserelin—Pain—Methotrexate—breast cancer	4.72e-05	8.1e-05	CcSEcCtD
Goserelin—Vomiting—Capecitabine—breast cancer	4.72e-05	8.09e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—breast cancer	4.71e-05	8.08e-05	CcSEcCtD
Goserelin—Shock—Doxorubicin—breast cancer	4.71e-05	8.07e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—MAPK3—breast cancer	4.7e-05	0.000219	CbGpPWpGaD
Goserelin—Nervous system disorder—Doxorubicin—breast cancer	4.69e-05	8.05e-05	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—breast cancer	4.68e-05	8.03e-05	CcSEcCtD
Goserelin—Rash—Capecitabine—breast cancer	4.68e-05	8.03e-05	CcSEcCtD
Goserelin—Insomnia—Epirubicin—breast cancer	4.68e-05	8.02e-05	CcSEcCtD
Goserelin—Dermatitis—Capecitabine—breast cancer	4.68e-05	8.02e-05	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—breast cancer	4.67e-05	8.01e-05	CcSEcCtD
Goserelin—Headache—Capecitabine—breast cancer	4.65e-05	7.97e-05	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—breast cancer	4.65e-05	7.97e-05	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—breast cancer	4.64e-05	7.96e-05	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—breast cancer	4.63e-05	7.93e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—BRAF—breast cancer	4.61e-05	0.000215	CbGpPWpGaD
Goserelin—Dyspnoea—Epirubicin—breast cancer	4.61e-05	7.91e-05	CcSEcCtD
Goserelin—Somnolence—Epirubicin—breast cancer	4.6e-05	7.88e-05	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—breast cancer	4.56e-05	7.82e-05	CcSEcCtD
Goserelin—Nausea—Docetaxel—breast cancer	4.55e-05	7.81e-05	CcSEcCtD
Goserelin—Feeling abnormal—Methotrexate—breast cancer	4.55e-05	7.81e-05	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—breast cancer	4.55e-05	7.81e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Methotrexate—breast cancer	4.52e-05	7.75e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SRC—breast cancer	4.5e-05	0.00021	CbGpPWpGaD
Goserelin—Decreased appetite—Epirubicin—breast cancer	4.49e-05	7.71e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—IGF1—breast cancer	4.49e-05	0.000209	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT2—breast cancer	4.49e-05	0.000209	CbGpPWpGaD
Goserelin—Hypotension—Doxorubicin—breast cancer	4.47e-05	7.67e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—EGFR—breast cancer	4.47e-05	0.000208	CbGpPWpGaD
Goserelin—Fatigue—Epirubicin—breast cancer	4.46e-05	7.65e-05	CcSEcCtD
Goserelin—Pain—Epirubicin—breast cancer	4.42e-05	7.58e-05	CcSEcCtD
Goserelin—Constipation—Epirubicin—breast cancer	4.42e-05	7.58e-05	CcSEcCtD
Goserelin—Nausea—Capecitabine—breast cancer	4.41e-05	7.56e-05	CcSEcCtD
Goserelin—Urticaria—Methotrexate—breast cancer	4.39e-05	7.53e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—VEGFA—breast cancer	4.38e-05	0.000204	CbGpPWpGaD
Goserelin—Body temperature increased—Methotrexate—breast cancer	4.37e-05	7.49e-05	CcSEcCtD
Goserelin—Abdominal pain—Methotrexate—breast cancer	4.37e-05	7.49e-05	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.36e-05	7.48e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—STAT3—breast cancer	4.34e-05	0.000202	CbGpPWpGaD
Goserelin—Insomnia—Doxorubicin—breast cancer	4.33e-05	7.42e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3CD—breast cancer	4.31e-05	0.000201	CbGpPWpGaD
Goserelin—Paraesthesia—Doxorubicin—breast cancer	4.3e-05	7.37e-05	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—breast cancer	4.27e-05	0.000199	CbGpPWpGaD
Goserelin—Dyspnoea—Doxorubicin—breast cancer	4.27e-05	7.31e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SERPINE1—breast cancer	4.27e-05	0.000199	CbGpPWpGaD
Goserelin—Feeling abnormal—Epirubicin—breast cancer	4.26e-05	7.31e-05	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—breast cancer	4.25e-05	7.29e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Epirubicin—breast cancer	4.23e-05	7.25e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—KRAS—breast cancer	4.22e-05	0.000197	CbGpPWpGaD
Goserelin—Dyspepsia—Doxorubicin—breast cancer	4.21e-05	7.22e-05	CcSEcCtD
Goserelin—Decreased appetite—Doxorubicin—breast cancer	4.16e-05	7.13e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MAPK3—breast cancer	4.15e-05	0.000193	CbGpPWpGaD
Goserelin—Fatigue—Doxorubicin—breast cancer	4.12e-05	7.07e-05	CcSEcCtD
Goserelin—Urticaria—Epirubicin—breast cancer	4.11e-05	7.04e-05	CcSEcCtD
Goserelin—Pain—Doxorubicin—breast cancer	4.09e-05	7.02e-05	CcSEcCtD
Goserelin—Constipation—Doxorubicin—breast cancer	4.09e-05	7.02e-05	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—breast cancer	4.09e-05	7.01e-05	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—breast cancer	4.09e-05	7.01e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—NOS3—breast cancer	4.07e-05	0.00019	CbGpPWpGaD
Goserelin—Hypersensitivity—Methotrexate—breast cancer	4.07e-05	6.98e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—MYC—breast cancer	4.03e-05	0.000188	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TGFB1—breast cancer	4.02e-05	0.000188	CbGpPWpGaD
Goserelin—Asthenia—Methotrexate—breast cancer	3.96e-05	6.8e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—EGFR—breast cancer	3.94e-05	0.000184	CbGpPWpGaD
Goserelin—Feeling abnormal—Doxorubicin—breast cancer	3.94e-05	6.76e-05	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—breast cancer	3.91e-05	6.71e-05	CcSEcCtD
Goserelin—Pruritus—Methotrexate—breast cancer	3.91e-05	6.7e-05	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—breast cancer	3.88e-05	0.000181	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MDM2—breast cancer	3.86e-05	0.00018	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RAF1—breast cancer	3.85e-05	0.000179	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RELA—breast cancer	3.83e-05	0.000179	CbGpPWpGaD
Goserelin—Hypersensitivity—Epirubicin—breast cancer	3.81e-05	6.53e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—ERBB2—breast cancer	3.81e-05	0.000178	CbGpPWpGaD
Goserelin—Urticaria—Doxorubicin—breast cancer	3.8e-05	6.52e-05	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—breast cancer	3.78e-05	6.49e-05	CcSEcCtD
Goserelin—Body temperature increased—Doxorubicin—breast cancer	3.78e-05	6.49e-05	CcSEcCtD
Goserelin—Diarrhoea—Methotrexate—breast cancer	3.78e-05	6.48e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PIK3CB—breast cancer	3.76e-05	0.000175	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MTOR—breast cancer	3.76e-05	0.000175	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KRAS—breast cancer	3.73e-05	0.000174	CbGpPWpGaD
Goserelin—Asthenia—Epirubicin—breast cancer	3.71e-05	6.36e-05	CcSEcCtD
Goserelin—Pruritus—Epirubicin—breast cancer	3.66e-05	6.27e-05	CcSEcCtD
Goserelin—Dizziness—Methotrexate—breast cancer	3.65e-05	6.27e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CXCL8—breast cancer	3.61e-05	0.000168	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—HRAS—breast cancer	3.59e-05	0.000167	CbGpPWpGaD
Goserelin—Diarrhoea—Epirubicin—breast cancer	3.54e-05	6.07e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CDKN1B—breast cancer	3.53e-05	0.000164	CbGpPWpGaD
Goserelin—Hypersensitivity—Doxorubicin—breast cancer	3.52e-05	6.05e-05	CcSEcCtD
Goserelin—Vomiting—Methotrexate—breast cancer	3.51e-05	6.02e-05	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—breast cancer	3.49e-05	0.000163	CbGpPWpGaD
Goserelin—Rash—Methotrexate—breast cancer	3.48e-05	5.97e-05	CcSEcCtD
Goserelin—Dermatitis—Methotrexate—breast cancer	3.48e-05	5.97e-05	CcSEcCtD
Goserelin—Headache—Methotrexate—breast cancer	3.46e-05	5.94e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CASP3—breast cancer	3.46e-05	0.000161	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL2—breast cancer	3.45e-05	0.000161	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6—breast cancer	3.43e-05	0.00016	CbGpPWpGaD
Goserelin—Asthenia—Doxorubicin—breast cancer	3.43e-05	5.89e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—breast cancer	3.42e-05	0.00016	CbGpPWpGaD
Goserelin—Dizziness—Epirubicin—breast cancer	3.42e-05	5.86e-05	CcSEcCtD
Goserelin—Pruritus—Doxorubicin—breast cancer	3.38e-05	5.8e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CCND1—breast cancer	3.37e-05	0.000157	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JUN—breast cancer	3.36e-05	0.000157	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CTNNB1—breast cancer	3.33e-05	0.000155	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—breast cancer	3.31e-05	0.000154	CbGpPWpGaD
Goserelin—Vomiting—Epirubicin—breast cancer	3.29e-05	5.64e-05	CcSEcCtD
Goserelin—Nausea—Methotrexate—breast cancer	3.28e-05	5.63e-05	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—breast cancer	3.27e-05	5.61e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MMP9—breast cancer	3.27e-05	0.000152	CbGpPWpGaD
Goserelin—Rash—Epirubicin—breast cancer	3.26e-05	5.59e-05	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—breast cancer	3.26e-05	5.59e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—CDKN1A—breast cancer	3.26e-05	0.000152	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTEN—breast cancer	3.25e-05	0.000151	CbGpPWpGaD
Goserelin—Headache—Epirubicin—breast cancer	3.24e-05	5.56e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—MAPK8—breast cancer	3.18e-05	0.000148	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AKT1—breast cancer	3.17e-05	0.000148	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HRAS—breast cancer	3.17e-05	0.000148	CbGpPWpGaD
Goserelin—Dizziness—Doxorubicin—breast cancer	3.16e-05	5.43e-05	CcSEcCtD
Goserelin—Nausea—Epirubicin—breast cancer	3.07e-05	5.27e-05	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—breast cancer	3.04e-05	5.22e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IL6—breast cancer	3.03e-05	0.000141	CbGpPWpGaD
Goserelin—Rash—Doxorubicin—breast cancer	3.02e-05	5.17e-05	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—breast cancer	3.01e-05	5.17e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—SRC—breast cancer	3.01e-05	0.00014	CbGpPWpGaD
Goserelin—Headache—Doxorubicin—breast cancer	3e-05	5.14e-05	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—VEGFA—breast cancer	2.93e-05	0.000137	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT3—breast cancer	2.9e-05	0.000135	CbGpPWpGaD
Goserelin—Nausea—Doxorubicin—breast cancer	2.84e-05	4.87e-05	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—AKT1—breast cancer	2.8e-05	0.00013	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK3—breast cancer	2.78e-05	0.000129	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MYC—breast cancer	2.7e-05	0.000126	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFB1—breast cancer	2.69e-05	0.000126	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGFR—breast cancer	2.64e-05	0.000123	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KRAS—breast cancer	2.49e-05	0.000116	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—breast cancer	2.29e-05	0.000107	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—breast cancer	2.22e-05	0.000103	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HRAS—breast cancer	2.12e-05	9.88e-05	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6—breast cancer	2.03e-05	9.46e-05	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT1—breast cancer	1.87e-05	8.73e-05	CbGpPWpGaD
